Results 11 to 20 of about 3,535 (191)

Patient utilization survey of mirabegron prescribed for overactive bladder [PDF]

Investigative and Clinical Urology, 2019
Purpose: Mirabegron, a β3-adrenoreceptor agonist, is used to treat overactive bladder. The factors affecting persistence of mirabegron use or symptom improvement are not thoroughly known, but could be related to patient characteristics.
Päivi Rahkola-Soisalo, Marcin Balcerzak, Jarno Ruotsalainen, Tomi S. Mikkola   +3 more
doaj   +2 more sources

A Modular Synthesis of C5‐Sulfenyl Thiazoles via an Intermolecular Pummerer Rearrangement: An Underexplored Scaffold for Medicinal Chemistry [PDF]

Angewandte Chemie, Volume 138, Issue 41, 5 October 2026.
Modular access to underexplored C5‐sulfenyl thiazoles via an intermolecular Pummerer rearrangement is reported. The methodology exhibits a broad functional group tolerance enabling the seamless design of trisubstituted thiazole cores bearing a sulfur handle for further elaboration.
Joe L. Smy, Theo C. Webb, Barnaby W. Greenland, S. Mark Roe, John Spencer, Storm Hassell‐Hart   +5 more
wiley   +3 more sources

Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist

Urological Science, 2015
Mirabegron, the first β3-adrenoceptor agonist introduced for use in clinical practice, differs from antimuscarinic agents in terms of mechanism of action. This review discusses various perspectives on mirabegron in terms of efficacy, mechanism of action,
Chia-Hao Kuei, Chung-Hsin Peng, Chun-Hou Liao   +2 more
doaj   +2 more sources

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta‐Analysis [PDF]

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1545-1555, November 2026.
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad, Raiyana Nuha, Shehab Khashaba, David Gillatt, Simon J. G. Lewis   +4 more
wiley   +2 more sources

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?

Journal of Urological Surgery, 2019
Oral pharmacotherapy constitutes second-line treatment for overactive bladder (OAB) after lifestyle modifications, bladder retraining, and pelvic floor muscle exercises. Antimuscarinics have an established role in the treatment of OAB.
Ömer Acar, Mustafa Levent Erton, Tufan Tarcan   +2 more
doaj   +2 more sources

Efficacy and Safety of Mirabegron 25 mg Versus Oral Desmopressin 120 mcg in Treatment of Primary Nocturnal Enuresis [PDF]

Urology Research and Practice
Objective: To evaluate the effectiveness and safety of mirabegron in the management of primary nocturnal enuresis. Methods: This prospective, randomized controlled study included 150 patients randomized into 2 equal groups: desmopressin and mirabegron.
Hosam Abdel-Fattah Abo- Elnasr, Mohamed Abdelrahman Alhefnawy, Mahmoud Farag, Mohamed Aboulfotouh El Gharably   +3 more
doaj   +2 more sources

Sex Differences in Prescribing Patterns of Anticholinergics and β3‐Adrenoceptor Agonists for Overactive Bladder: A Nationwide Study in Japan, FY2017–FY2024 [PDF]

LUTS: Lower Urinary Tract Symptoms, Volume 18, Issue 6, November 2026.
ABSTRACT Objectives Drug treatment for overactive bladder (OAB) is changing, with an increasing share of β3‐adrenoceptor agonists relative to anticholinergics, but it is not known how far this change has progressed in older people, who are most vulnerable to the risks of anticholinergics.
Toshikazu Koike, Takashi Kawahara, Akihito Hashizume, Masanobu Yamazaki, Daiji Takamoto, Hiroki Ito, Teppei Takeshima, Hiroji Uemura, Kazuhide Makiyama, Jun‐Ichi Teranishi   +9 more
wiley   +2 more sources

Beta‐3 Adrenoreceptor Agonist Mirabegron Improves Right Ventricular Function in a Rat Monocrotaline‐Induced Pulmonary Hypertension Model [PDF]

Pulmonary Circulation
Considering the beta‐3 adrenoceptor agonist, mirabegron, may display vasodilator and cardioprotective properties, we investigated the therapeutic potential of mirabegron in monocrotaline‐induced pulmonary hypertension in rats.
Pedro Mendes‐Ferreira, Birger Tielemans, Allard Wagenaar, Caroline Bouzin, Rui Adão, Peter Pokreisz, Delphine De Mulder, Adelino Leite‐Moreira, Carmen Brás‐Silva, Jean‐Luc Balligand, Chantal Dessy, Marion Delcroix, Rozenn Quarck, Catharina Belge   +13 more
doaj   +2 more sources

Efficacy and safety of mirabegron versus solifenacin in the treatment of overactive bladder in children: a systematic review and meta-analysis [PDF]

BMC Urology
Background Overactive bladder (OAB) affects 5–12% of children and is associated with urgency, frequency, and incontinence, often leading to psychosocial distress. Antimuscarinics are widely used but limited by systemic side effects.
Mostafa Shaheen, Omar Mohamed Ali, Abdullah A. Draz, Amro K. Barakat, Ahmed Elghattas, Toqa Elbaz, Iyad Walid, Tasnim Tarboush, Asmaa Elsayed, Tasneem Mahmoud, Esraa Mohamed Elkhateeb, Abdallah Adel Nofal, Emad Samaan   +12 more
doaj   +2 more sources

Sex‐ and Age‐Specific Trends in Prescriptions of Beta‐3 Agonists and Anticholinergics in Japan: A Nationwide Prescription Database Study [PDF]

LUTS: Lower Urinary Tract Symptoms, Volume 18, Issue 5, September 2026.
ABSTRACT Introduction To investigate the nationwide trends in pharmacological treatment for overactive bladder among Japanese adults, specifically focusing on the β3‐agonists to anticholinergics prescribed tablet ratio (BAPR) and how this ratio differs by sex and age.
Minato Yokoyama, Ayaka Onuki, Kisaki Koshi, Sorami Tsukahara, Haruko Negami, Keiji Shiba, Yuichiro Kato, Akihiro Kojima, Daisuke Kato, Takumasa Amemiya, Tsunehiro Nenohi, Masayasu Urushibara, Motohiro Fujiwara, Touko Asano, Hideto Kano, Kazuhiro Ishizaka   +15 more
wiley   +2 more sources